Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Kort integrativ och neurokognitiv terapi för unga vuxna med borderline personlighetsstörning (SINTYA)

10 november 2026 uppdaterad av: Centre Hospitalier Universitaire de Nīmes

Kort integrativ och neurokognitiv terapi för unga vuxna med borderline personlighetsstörning: en studiemodell för impulsivitetshantering

Borderline personality disorder (BPD) is a severe, high-suicidal psychiatric disorder associated with impulsive, endangering behaviors. Young patients between 16 and 25 years old do not respond to traditional psychotherapies, which are often long and not adapted to their neurocognitive alterations linked to early trauma. The study authors hypothesize the SINTYA therapy program (one group session and one individual session weekly for 10 weeks) would reduce the level of impulsivity and clinical symptomatology (severity of the BPD; emotional regulation difficulties; dissociative symptoms; aggressiveness; ruminations; the number of self-destructive behaviors and suicidal acts; impulsive behaviors; level of suicide risk and hopelessness; the number of psychiatric hospitalizations and emergency visits for psychiatric reasons; and finally improving psychosocial functioning).

Studieöversikt

Status

Avslutad

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Faktisk)

74

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

16 år till 25 år (Barn, Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Diagnosis of BPD according to DSM-5 criteria and BPQ-80 scale.
  • High BPD severity level: ZAN-BPD (score ≥ 18/36).
  • Understand, write and read French.
  • Be able to understand the nature, purpose and methodology of the study and agree to cooperate during evaluations.
  • Have signed the informed consent.
  • For minor patients, have signed the parental consent by at least one holder of parental authority.

Exclusion Criteria:

  • Refusal to participate.
  • Existence of a neurological pathology or cerebral sequelae of organic origin which could affect neurocognitive performance.
  • Intelligence quotient < 70.
  • Lifetime diagnosis of schizoaffective disorder or schizophrenia (MINI-7).
  • Previous or current participation in specific psychotherapy for BPD.
  • Subject deprived of liberty (by judicial or administrative decision) and/or protected by law.
  • Inclusion in another study including psychotherapy for the duration of the study.
  • Inclusion in a drug RIPH1 study or in a REC study (European regulation of clinical trials) for the entire duration of the study.
  • Subject in period of exclusion from another research protocol.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Inget ingripande: Kontrollera
Experimentell: SINTYA grupp

10-week psychotherapy program consisting of a weekly 1h30 hour group therapy session plus 1 hour individual therapy session

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Variation in explicit impulsivity between groups
Tidsram: Baseline

UPPS-S (Impulsive Behavior Scale Short version score)

Baseline
Variation in explicit impulsivity between groups
Tidsram: Month 4

UPPS-S (Impulsive Behavior Scale Short version score)

Month 4

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Variation in explicit impulsivity between groups
Tidsram: Month 7

UPPS-S (Impulsive Behavior Scale Short version score)

Month 7
Variation in impulsiveness between groups
Tidsram: Baseline

Barratt Impulsiveness Scale (BIS-11) (score out of 120)

Baseline
Variation in impulsiveness between groups
Tidsram: Month 4

Barratt Impulsiveness Scale (BIS-11) (score out of 120)

Month 4
Variation in impulsiveness between groups
Tidsram: Month 7

Barratt Impulsiveness Scale (BIS-11) (score out of 120)

Month 7
BPD severity level between groups
Tidsram: Baseline

Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36)

Baseline
BPD severity level between groups
Tidsram: Month 4

Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36)

Month 4
BPD severity level between groups
Tidsram: Month 7

Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36)

Month 7
Emotional regulation capacities between groups
Tidsram: Baseline

Difficulties in Emotion Regulation Scale (DERS-18)

Baseline
Emotional regulation capacities between groups
Tidsram: Month 4

Difficulties in Emotion Regulation Scale (DERS-18)

Month 4
Emotional regulation capacities between groups
Tidsram: Month 7

Difficulties in Emotion Regulation Scale (DERS-18)

Month 7
Dissociative symptoms between groups
Tidsram: Baseline

Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder

Baseline
Dissociative symptoms between groups
Tidsram: Month 4

Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder

Month 4
Dissociative symptoms between groups
Tidsram: Month 7

Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder

Month 7
Aggression between groups
Tidsram: Baseline

Aggression Questionnaire (AQ-12)

Baseline
Aggression between groups
Tidsram: Month 4

Aggression Questionnaire (AQ-12)

Month 4
Aggression between groups
Tidsram: Month 7

Aggression Questionnaire (AQ-12)

Month 7
Ruminations between groups
Tidsram: Baseline

Rumination Reflection Questionnaire (RRQ)

Baseline
Ruminations between groups
Tidsram: Month 4

Rumination Reflection Questionnaire (RRQ)

Month 4
Ruminations between groups
Tidsram: Month 7

Rumination Reflection Questionnaire (RRQ)

Month 7
Number of self-destructive behaviors between groups
Tidsram: Baseline

Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview

Baseline
Number of self-destructive behaviors between groups
Tidsram: Month 4

Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview

Month 4
Number of self-destructive behaviors between groups
Tidsram: Month 7

Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview

Month 7
Number of impulsive behaviors between groups
Tidsram: Baseline

Number of impulsive behaviors (food, motor vehicles, sexual, drug-related)

Baseline
Number of impulsive behaviors between groups
Tidsram: Month 4

Number of impulsive behaviors (food, motor vehicles, sexual, drug-related)

Month 4
Number of impulsive behaviors between groups
Tidsram: Month 7

Number of impulsive behaviors (food, motor vehicles, sexual, drug-related)

Month 7
Level of suicide risk between groups
Tidsram: Baseline

Columbia-Suicide Severity Rating Scale (C-SSRS)

Baseline
Level of suicide risk between groups
Tidsram: Month 4

Columbia-Suicide Severity Rating Scale (C-SSRS)

Month 4
Level of suicide risk between groups
Tidsram: Month 7

Columbia-Suicide Severity Rating Scale (C-SSRS)

Month 7
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Tidsram: 12 Months prior to inclusion

Information taken from patient medical file

12 Months prior to inclusion
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Tidsram: Baseline

Information taken from patient medical file

Baseline
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Tidsram: Month 4

Information taken from patient medical file

Month 4
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Tidsram: Month 7

Information taken from patient medical file

Month 7
Psychosocial functioning between groups
Tidsram: Baseline

Functional Assessment Staging Tool (FAST)

Baseline
Psychosocial functioning between groups
Tidsram: Month 4

Functional Assessment Staging Tool (FAST)

Month 4
Psychosocial functioning between groups
Tidsram: Month 7

Functional Assessment Staging Tool (FAST)

Month 7
Implicit impulsivity between groups
Tidsram: Baseline

Continuous Performance Test (CPT)

Baseline
Implicit impulsivity between groups
Tidsram: Month 4

Continuous Performance Test (CPT)

Month 4
Implicit impulsivity between groups
Tidsram: Month 7

Continuous Performance Test (CPT)

Month 7
Neurocognitive evaluation of implicit impulsivity between groups
Tidsram: Baseline

Emotional Stroop (SE) customized to the study

Baseline
Neurocognitive evaluation of implicit impulsivity between groups
Tidsram: Month 4

Emotional Stroop (SE) customized to the study

Month 4
Neurocognitive evaluation of implicit impulsivity between groups
Tidsram: Month 7

Emotional Stroop (SE) customized to the study

Month 7
Risk taking between groups
Tidsram: Baseline

Balloon Analogue Risk Task (BART)

Baseline
Risk taking between groups
Tidsram: Month 4

Balloon Analogue Risk Task (BART)

Month 4
Risk taking between groups
Tidsram: Month 7

Balloon Analogue Risk Task (BART)

Month 7
Decision making under risk conditions between groups
Tidsram: Baseline

Game Dice Task (GDT)

Baseline
Decision making under risk conditions between groups
Tidsram: Month 4

Game Dice Task (GDT)

Month 4
Decision making under risk conditions between groups
Tidsram: Month 7

Game Dice Task (GDT)

Month 7

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Clémentine Estric, CHU de Nimes

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

8 november 2023

Primärt slutförande (Faktisk)

13 september 2025

Avslutad studie (Faktisk)

22 december 2025

Studieregistreringsdatum

Först inskickad

22 maj 2023

Först inskickad som uppfyllde QC-kriterierna

12 juni 2023

Första postat (Faktisk)

22 juni 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

13 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • NIMAO/2022-1/CE-01

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

All IPD that underlie results in a publication

Tidsram för IPD-delning

Upon publication

Kriterier för IPD Sharing Access

The IPD will be made available to other researchers upon reasonable request to the corresponding author

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV
  • ICF
  • ANALYTIC_CODE

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera